An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Tuscaloosa Research & Education Advancement Corporation
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Lori Davis, MD, Tuscaloosa Research & Education Advancement Corporation
ClinicalTrials.gov Identifier:
NCT01587118
First received: April 25, 2012
Last updated: November 26, 2013
Last verified: November 2013
  Purpose

This is an open label pilot study of adjunctive asenapine for the treatment of Posttraumatic Stress Disorder (PTSD) in veterans who have not fully remitted to an adequate trial of standard serotonin-specific reuptake inhibitor (SSRI) treatment.


Condition Intervention Phase
Posttraumatic Stress Disorder
Drug: Adjunctive asenapine
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

Resource links provided by NLM:


Further study details as provided by Tuscaloosa Research & Education Advancement Corporation:

Primary Outcome Measures:
  • Reduction in Clinical Administered PTSD Scale (CAPS)Score [ Time Frame: baseline, 4, 8, and 12 weeks ] [ Designated as safety issue: No ]
    Asenapine-treated subjects with PTSD will have significantly reduced PTSD symptoms (Clinician Administered PTSD Scale [CAPS] total and Davidson Trauma Scale).


Estimated Enrollment: 20
Study Start Date: June 2012
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SSRI plus adjunctive asenapine
Participants on SSRI therapy for PTSD with ongoing symptoms will receive adjunctive asenapine
Drug: Adjunctive asenapine
participants stable on SSRI therapy for PTSD will receive adjunctive asenapine 5 mg sublingual twice per day, titrated up to 10 mg twice per day, as tolerated for a total of 12 weeks.
Other Names:
  • asenapine
  • Saphris

Detailed Description:

An open label pilot study of adjunctive asenapine for the treatment of PTSD in veterans who have not fully remitted to an adequate trial of standard serotonin-specific reuptake inhibitor (SSRI) treatment.

  Eligibility

Ages Eligible for Study:   19 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed and dated informed consent and acceptable proof of identity.
  • Male or female subjects ≥19 to 65 years of age of any race or ethnic origin.
  • Not currently pregnant, breastfeeding or planning on becoming pregnant; use of contraception as follows:
  • Males - those that are sexually active must use a double barrier method of contraception (condom with spermicide) from the first dose of SSRI until 12 weeks after last dose of SSRI + asenapine
  • Women of child-bearing potential - must have a negative urine pregnancy test and confirmed (by the investigator) use of a highly effective form of birth control for 3 months before enrollment and until 12 weeks after their last dose of SSRI+asenapine.
  • Women of non-child bearing potential - women who are either permanently sterilized (hysterectomy, bilateral oophorectomy and bilateral salpingectomy but excluding bilateral tubal occlusion) or who are postmenopausal.
  • Diagnosis of PTSD (DSM-IV-TR criteria; confirmed by MINI and CAPS).
  • Total CAPS score > 45.
  • Currently taking an approved SSRI at acceptable dose for 8 weeks or more with non-remission of symptoms.
  • No substance use disorders of dependence (except for nicotine, caffeine) in previous 4 wks.
  • No substance use disorders of abuse (except for nicotine and caffeine) in the previous 2 wks.
  • Physical and laboratory panel (within past one year) are within normal limits or not clinically significant

Exclusion Criteria:

  • Lifetime history of bipolar I, schizophrenia, schizoaffective or cognitive disorders (assessed by the MINI)
  • Actively considering plans of suicide or homicide (assessed by clinical interview)
  • Psychotic symptoms that in the investigator's opinion impair the subject's ability to give informed consent
  • A contraindication to the use of asenapine or SSRI
  • Intolerable side effects or allergic reaction to asenapine or the current SSRI
  • Women planning to become pregnant or breastfeed during the study
  • Clinically significant unstable or severe medical condition that would contraindicate study participation or expose them to an undue risk of a significant adverse event, including but not limited to: unstable or severe hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, or hematologic disease; hypo- or hyperthyroidism, unless the condition has been stabilized; or a history of seizures (except for a single childhood febrile seizure, posttraumatic, or alcohol withdrawal). The following are exclusionary: platelets < 75,000/mm; hemoglobin <9g/dL; neutrophils, absolute < 1000/mm; LFTs > 3x upper limit; creatinine > 2 mg/dL; diastolic BP < 60 or > 110mmHg; EKG QTc > 475 msec.
  • In regard to vulnerable patient populations, persons with dementia, minors (<age 19), the elderly (>age 65), prisoners and the terminally ill are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01587118

Contacts
Contact: Lori L Davis, MD 205-554-2000 ext 3819 lori.davis@va.gov
Contact: Patricia D Pilkinton, MD 205-554-2000 ext 2944 patricia.pilkinton@va.gov

Locations
United States, Alabama
Tuscaloosa VA Medical Center Recruiting
Tuscaloosa, Alabama, United States, 35404
Contact: Patricia Pilkinton, MD    205-554-2000 ext 2944      
Sponsors and Collaborators
Lori Davis, MD
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Lori L Davis, MD Tuscaloosa Research & Education Advancement Corporation
  More Information

No publications provided

Responsible Party: Lori Davis, MD, Associate Chief of Staff, Research and Development Service, Tuscaloosa Research & Education Advancement Corporation
ClinicalTrials.gov Identifier: NCT01587118     History of Changes
Other Study ID Numbers: 00156
Study First Received: April 25, 2012
Last Updated: November 26, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Tuscaloosa Research & Education Advancement Corporation:
PTSD
Posttraumatic Stress Disorder
Asenapine
Adjunctive
SSRI

Additional relevant MeSH terms:
Stress Disorders, Post-Traumatic
Stress Disorders, Traumatic
Anxiety Disorders
Mental Disorders
Asenapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on August 28, 2014